-
Merbromin as a Selective SARS-CoV-2 3CLpro Inhibitor
2026-08-27
Chen and colleagues identified Merbromin as a selective in vitro inhibitor of the SARS-CoV-2 chymotrypsin-like protease 3CLpro through screening of approximately 6,000 compounds. Kinetic, binding, and docking analyses supported a mixed-type inhibition model involving more than one interaction site, providing a mechanistic starting point for antiviral inhibitor development.
-
BEND Lipids for mRNA Delivery and Gene Editing
2026-08-27
The reference study introduces branched endosomal disruptor (BEND) ionizable lipids that improve lipid nanoparticle delivery of mRNA and CRISPR-Cas9 ribonucleoproteins. Its complementary hepatic and T-cell experiments link terminal lipid branching to stronger endosomal penetration, enhanced transfection, and more effective gene editing compared with non-branched lipid designs.
-
iPSC-Based Trial Selection for Ultrarare Disease
2026-08-26
Sequiera et al. developed a patient-specific iPSC platform to prescreen therapies for an 18-year-old with Leigh-like syndrome caused by ultrarare ECHS1 variants. The study shows how matched patient and control models can reduce uncertainty before clinical trial enrollment, although broader validation is needed before routine clinical adoption.
-
Nigericin Sodium Salt: Practical Workflow
2026-08-26
Nigericin sodium salt is a potassium ionophore for controlled K+/H+ exchange across biological membranes, supporting experiments on cytoplasmic pH regulation, platelet aggregation modulation, and lead (Pb2+) ion transport. This dossier-based guide covers preparation and assay controls, while emphasizing that the compound is for research use only and is not a validated treatment for lead intoxication or a universal reagent for every cell model.
-
Mitoxantrone Targets the ERα DBD–LBD Interface
2026-08-25
Wang et al. identify mitoxantrone as a ligand for an underexplored interface between the estrogen receptor alpha DNA-binding and ligand-binding domains. The study shows that this interaction alters receptor conformation, promotes cytoplasmic redistribution and proteasomal degradation, and suppresses endocrine-resistant ERα activity through a mechanism distinct from DNA damage.
-
Asunaprevir Workflows for HCV NS3 Research
2026-08-25
Asunaprevir (BMS-650032) supports a practical, tiered workflow spanning NS3/4A protease biochemistry, HCV RNA replication inhibition, genotype profiling, and host-response controls. This guide combines product-specific handling advice with a reporter-first screening concept from a separate cancer study, while clearly distinguishing established evidence from assay-development recommendations.
-
EdU Imaging Kits (Cy5) for S-Phase Assays
2026-08-24
Measure DNA synthesis with a morphology-preserving click-chemistry workflow designed for fluorescence microscopy and flow cytometry. EdU Imaging Kits (Cy5) offer a practical alternative to BrdU assays when researchers need sensitive proliferation data alongside intact antigen-binding sites.
-
N3-kethoxal: From Probe to Readout Design
2026-08-24
N3-kethoxal converts exposed guanine bases into covalently tagged molecular coordinates for RNA structure probing and accessible-DNA analysis. This guide explains how its chemistry informs assay selection, KAS-ATAC interpretation, controls, and translational workflow design.
-
Adefovir (GS-0393) for HBV Research
2026-08-23
Adefovir (GS-0393) combines a defined HBV DNA polymerase mechanism with a practical OAT1 transporter-probe application. This guide translates those properties into reproducible antiviral, uptake, and translational safety workflows while addressing formulation and interpretation risks.
-
BMS 309403: Practical FABP4 Inhibitor Workflows
2026-08-22
Use BMS 309403 to dissect how FABP4 connects fatty-acid handling with macrophage inflammation, foam-cell formation, and metabolic dysfunction. This guide combines pathway-focused assay design, dose and time optimization, translational comparisons, and troubleshooting for atherosclerosis and type 2 diabetes research.
-
Fluconazole as a Resistance-Aware Research Tool
2026-08-21
Fluconazole is more than a conventional azole control: it is a mechanistically defined perturbation for linking ergosterol disruption to fungal phenotypes. This article presents a resistance-aware framework for susceptibility assays, Candida models, formulation, and interpretation using evidence from a clinically relevant Candida auris study.
-
Angiotensin (1-7): Assay Design & New RAS Insight
2026-08-20
Explore how Angiotensin (1-7) connects Mas-receptor biology with emerging peptide–viral receptor binding data. This evidence-focused guide translates sequence, pathway, handling, and assay considerations into better experimental decisions.
-
MG-262 Proteasome Inhibition Workflows
2026-08-20
MG-262 enables reversible, cell-permeable disruption of proteasome chymotryptic activity for proteostasis, apoptosis, cell-cycle, and osteoclast studies. This workflow-focused guide connects proteasome perturbation with the reference study’s skeletal-muscle chaperone-mediated autophagy findings while emphasizing controls, washout experiments, and troubleshooting.
-
Acifran Workflows for HCAR Signaling Research
2026-08-19
Acifran enables controlled interrogation of HM74A/GPR109A and GPR109B signaling across receptor, cAMP, and lipid-metabolism workflows. This practical guide translates recent cryo-EM findings into assay design, dosing, controls, and troubleshooting choices for reproducible metabolic disorder research.
-
Paroxetine Mesylate: From SSRI to Translational Tool
2026-08-19
Paroxetine Mesylate is more than a Selective serotonin reuptake inhibitor. Its SERT activity, cytochrome P450 inhibition, and kinase-related pharmacology create a valuable platform for studying colorectal cancer biology, exposure–response relationships, and cross-domain translational questions.